Characteristics of patients with CLL
| Patient rank . | NMFI . | Cell lysis (%) . | Age (y) . | IGHV mutation . | Cytogenetics . | CLL cells (%) . | Patient no. . |
|---|---|---|---|---|---|---|---|
| 1 | 0.9 | 0 | 66 | No | +12 | 89 | 5 |
| 2 | 1.5 | 7 | 91 | Yes | — | 36 | 4 |
| 3 | 2.5 | 47 | 54 | Yes | del13q | 24 | 1 |
| 4 | 3.0 | 57 | 53 | Yes | — | 84 | 9 |
| 5 | 7.2 | 31 | 90 | Yes | del13q | 89 | 3 |
| 6 | 7.5 | 49 | 48 | No | del11q | 96 | 7 |
| 7 | 15.5 | 41 | 61 | Yes | — | 60 | 10 |
| 8 | 18.5 | 73 | 58 | Yes | — | 79 | 2 |
| 9 | 32.6 | 70 | 60 | Yes | — | 69 | 8 |
| 10 | 39.6 | 77 | 66 | Yes | +12 | 96 | 6 |
| Patient rank . | NMFI . | Cell lysis (%) . | Age (y) . | IGHV mutation . | Cytogenetics . | CLL cells (%) . | Patient no. . |
|---|---|---|---|---|---|---|---|
| 1 | 0.9 | 0 | 66 | No | +12 | 89 | 5 |
| 2 | 1.5 | 7 | 91 | Yes | — | 36 | 4 |
| 3 | 2.5 | 47 | 54 | Yes | del13q | 24 | 1 |
| 4 | 3.0 | 57 | 53 | Yes | — | 84 | 9 |
| 5 | 7.2 | 31 | 90 | Yes | del13q | 89 | 3 |
| 6 | 7.5 | 49 | 48 | No | del11q | 96 | 7 |
| 7 | 15.5 | 41 | 61 | Yes | — | 60 | 10 |
| 8 | 18.5 | 73 | 58 | Yes | — | 79 | 2 |
| 9 | 32.6 | 70 | 60 | Yes | — | 69 | 8 |
| 10 | 39.6 | 77 | 66 | Yes | +12 | 96 | 6 |
Siglec-6 expression was analyzed in 10 treatment-naïve patients with CLL. Cytolytic activity against primary B-CLL cells was analyzed in a flow cytometry-based assay after 4 hours of coculture. CLL cells (%) values refer to the frequency in peripheral blood.